Showing 3921-3930 of 4165 results for "".
- New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced AMD Progressionhttps://modernod.com/news/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-amd-progression/2479193/Bausch + Lomb announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edemahttps://modernod.com/news/lumithera-presents-valeda-treatment-benefits-for-photobiomodulation-in-early-patients-with-diabetic-retinopathy-and-macular-edema/2479177/LumiThera announced research investigators presented positive clinical findings following PBM treatment with the Valeda Light Delivery System from an ongoing safety and efficacy study in early diabetic retinopathy (DR) patients with central macular edema (DME) at the Association for Research in V
- Surface Ophthalmics’ Chronic Dry Eye Study Reaches 50% Enrollment Milestonehttps://modernod.com/news/surface-ophthalmics-chronic-dry-eye-study-reaches-50-enrollment-milestone/2479173/Surface Ophthalmics, Inc. today announced that 50% of patients have been enrolled and randomized in the Phase II clinical trial for its investigational product SURF-100 (mycophenolate sodium and betamethasone sodium phosphate in Klarity vehicle) for the treatment of chronic dry eye disease. Havin
- Okogen Announces Interim Analysis Results From RUBY Phase 2 Trial for Acute Adenoviral Conjunctivitis Drug Candidatehttps://modernod.com/news/okogen-announces-interim-analysis-results-from-ruby-phase-2-trial-for-acute-adenoviral-conjunctivitis-drug-candidate/2479140/Okogen announced the interim analysis results from RUBY, the company’s phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301
- Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Trial of AR-15512 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-for-the-treatment-of-patients-with-dry-eye-disease/2479134/Aerie Pharmaceuticals announced the completion of patient enrollment for COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 Agonist) ophthalmic solution for the treatment of patients with dry eye disease. The first patient to enter this randomized, double-masked, vehicle-controlled phas
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollmenthttps://modernod.com/news/nicoxs-ncx-4251-mississippi-phase-2b-blepharitis-trial-reaches-50-enrollment/2479109/Nicox SA announced that 102 patients in the NCX 4251 Mississippi phase 2b blepharitis clinical trial have now been randomized out of a target of 200, with topline results currently on track to be announced during Q4 2021. “Achievement of 50% enrollment in this phase 2b trial of NCX 4251 in
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- Surface Ophthalmics Announces Preeya K. Gupta, MD, as Chief Medical Advisorhttps://modernod.com/news/surface-ophthalmics-announces-preeya-k-gupta-md-as-chief-medical-advisor/2479032/Surface Ophthalmics announced the appointment of Preeya K. Gupta, MD, as Chief Medical Advisor (CMA). Dr. Gupta will consult with Surface Ophthalmics leaders and lend her expertise, particularly in dry eye disease, to help guide Surface’s three clinical progra
- AffaMed Therapeutics Completes $170 Million Series B Financing to Further Development of Ophthalmic and Neuroscience Pipelinehttps://modernod.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/AffaMed Therapeutics announced the completion of over $170 million in Series B financing. Proceeds from the financing will be used to advance clinical development of AffaMed’s pipeline of innovative therapeutic candidates, progress business development and partnering activities, and support